These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32391919)

  • 21. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
    Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial.
    Viscoli C; Castagnola E; Van Lint MT; Moroni C; Garaventa A; Rossi MR; Fanci R; Menichetti F; Caselli D; Giacchino M; Congiu M
    Eur J Cancer; 1996 May; 32A(5):814-20. PubMed ID: 9081359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
    Glasmacher A; Prentice AG
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i23-i32. PubMed ID: 16120631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial.
    Oyake T; Kowata S; Murai K; Ito S; Akagi T; Kubo K; Sawada K; Ishida Y
    Eur J Haematol; 2016 Jun; 96(6):602-9. PubMed ID: 26216048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia.
    Fung M; Kim J; Marty FM; Schwarzinger M; Koo S
    PLoS One; 2015; 10(11):e0140930. PubMed ID: 26554923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients.
    Prentice HG; Hann IM; Herbrecht R; Aoun M; Kvaloy S; Catovsky D; Pinkerton CR; Schey SA; Jacobs F; Oakhill A; Stevens RF; Darbyshire PJ; Gibson BE
    Br J Haematol; 1997 Sep; 98(3):711-8. PubMed ID: 9332329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections.
    Yilmaz D; Balkan C; Ay Y; Akin M; Karapinar B; Kavakli K
    Mycoses; 2011 May; 54(3):234-42. PubMed ID: 19906090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EPICO 3.0. Empirical antifungal therapy in critically-ill hematology patients.
    Llinares P; Ruiz I; Zaragoza R; Ferrer R; Rodríguez AH; Maseda E; Grau S;
    Rev Iberoam Micol; 2016; 33(4):206-215. PubMed ID: 27751781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study.
    Candoni A; Caira M; Cesaro S; Busca A; Giacchino M; Fanci R; Delia M; Nosari A; Bonini A; Cattaneo C; Melillo L; Caramatti C; Milone G; Scime' R; Picardi M; Fanin R; Pagano L;
    Mycoses; 2014 Jun; 57(6):342-50. PubMed ID: 24373120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group.
    Morgenstern GR; Prentice AG; Prentice HG; Ropner JE; Schey SA; Warnock DW
    Br J Haematol; 1999 Jun; 105(4):901-11. PubMed ID: 10554799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An open-label non-inferiority randomised control trial comparing nebulised amphotericin B with oral itraconazole in patients with pulmonary aspergilloma.
    Ray A; Manikanta J; Singh K; Gabra P; Vyas S; Singh G; Xess I; Sethi P; Meena VP; Soneja M; Sinha S; Wig N; Kabra SK
    Mycoses; 2021 Sep; 64(9):1038-1044. PubMed ID: 34058036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical study of intravenous injecting itraconazole as empirical antifungal therapy for patients with hematological malignancies].
    Luo CW; DU X; Guo R; Weng JY; Lu ZS; Wu SJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):1000-4. PubMed ID: 22931672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized comparative trial evaluating the safety and efficacy of liposomal amphotericin B (Fungisome) versus conventional amphotericin B in the empirical treatment of febrile neutropenia in India.
    Jadhav MP; Shinde VM; Chandrakala S; Jijina F; Menon H; Arora B; Kurkure PA; Parikh PM; Kshirsagar NA
    Indian J Cancer; 2012; 49(1):107-13. PubMed ID: 22842177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis.
    Caillot D
    Acta Haematol; 2003; 109(3):111-8. PubMed ID: 12714819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients.
    Nucci M; Biasoli I; Akiti T; Silveira F; Solza C; Barreiros G; Spector N; Derossi A; Pulcheri W
    Clin Infect Dis; 2000 Feb; 30(2):300-5. PubMed ID: 10671332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia.
    Malik IA; Moid I; Aziz Z; Khan S; Suleman M
    Am J Med; 1998 Dec; 105(6):478-83. PubMed ID: 9870832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia.
    Lafaurie M; Lapalu J; Raffoux E; Breton B; Lacroix C; Socié G; Porcher R; Ribaud P; Touratier S; Molina JM
    Clin Microbiol Infect; 2010 Aug; 16(8):1191-6. PubMed ID: 19735276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. D-Index-Guided Early Antifungal Therapy Versus Empiric Antifungal Therapy for Persistent Febrile Neutropenia: A Randomized Controlled Noninferiority Trial.
    Kanda Y; Kimura SI; Iino M; Fukuda T; Sakaida E; Oyake T; Yamaguchi H; Fujiwara SI; Jo Y; Okamoto A; Fujita H; Takamatsu Y; Saburi Y; Matsumura I; Yamanouchi J; Shiratori S; Gotoh M; Nakamura S; Tamura K;
    J Clin Oncol; 2020 Mar; 38(8):815-822. PubMed ID: 31977270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia.
    Al-Badriyeh D; Liew D; Stewart K; Kong DC
    J Antimicrob Chemother; 2009 Jan; 63(1):197-208. PubMed ID: 19001450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer.
    Winston DJ; Hathorn JW; Schuster MG; Schiller GJ; Territo MC
    Am J Med; 2000 Mar; 108(4):282-9. PubMed ID: 11014720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.